Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC
Name:
1-s2.0-S1556086419335294-main.pdf
Size:
1.308Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
Gray, JEVillegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
Cho, BC
Planchard, D
Paz-Ares, L
Faivre-Finn, Corinne
Vansteenkiste, JF
Spigel, DR
Wadsworth, C
Taboada, M
Dennis, PA
Ozguroglu, M
Antonia, SJ
Affiliation
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.Issue Date
2019
Metadata
Show full item recordCitation
Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC. J Thorac Oncol. 2019.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2019.10.002PubMed ID
31622733Additional Links
https://dx.doi.org/10.1016/j.jtho.2019.10.002Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2019.10.002
Scopus Count
Collections
Related articles
- Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
- Authors: Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroğlu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ
- Issue date: 2021 May
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
- Authors: Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ
- Issue date: 2022 Apr 20
- Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
- Authors: Naidoo J, Antonia S, Wu YL, Cho BC, Thiyagarajah P, Mann H, Newton M, Faivre-Finn C
- Issue date: 2023 May
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
- Authors: Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M, PACIFIC Investigators
- Issue date: 2018 Dec 13
- Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
- Authors: Socinski MA, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray JE, Park K, Vincent M, Mann H, Newton M, Dennis PA, Antonia SJ
- Issue date: 2021 Nov